← Back to VTS Methodology
VTS Scoring Log

Nexaph

nexaph.com · Est. 2024 · United States · Scored August 2026

Nexaph uses Janoshik Analytical for third-party testing and publishes results at nexaph.com/lab-result/, with a dedicated COA portal at nexaph.coa.swiftcs.ai searchable by lot number. NXP-prefix batch identifiers provide a structured traceability format. An age-gate on the main site is a checkbox confirmation rather than a real account requirement, leaving the COA library effectively publicly accessible. The score is constrained by several gaps: no company name, founders, or team is disclosed anywhere on the site; Finnrick and third-party review sources trace the vendor across multiple domain variants with no public explanation; the refund policy requires researchers to submit independent laboratory proof before a quality claim can be considered; and one publicly documented independent test returned 70% purity on a product the vendor claims at 99%. Finnrick tracks 265 tests across 11 products with a median purity of 99.7% on passing samples - but the 70% outlier, and the vendor-controlled selection of which Janoshik results are made public, are meaningful caveats.

63 /100
Moderate
Janoshik named, public COA results page, NXP batch IDs. Limited by anonymous operator identity across fragmented domain set, refund requiring independent lab proof, and one independent test at 70% on a 99%-claimed product.
Dimension Scores
DimensionMaxNotesScore
Third-Party Testing Practice 30 Janoshik Analytical named as primary testing lab. HPLC and mass spectrometry confirmed. Janoshik publishes results publicly with verifiable task IDs, enabling cross-check independent of the vendor. Finnrick tracks 265 tests across 11 products with a median purity of 99.7% on passing samples. Deductions applied for: (1) vendor-controlled Janoshik publication model - the vendor selects which batch results go public, meaning a researcher cannot independently verify all batches were tested; (2) one publicly documented independent test returning 70% purity on a product claimed at 99%, raising questions about batch consistency or selective testing; (3) possible link to Chinese pharmaceutical sourcing per published third-party analysis. 18/30
Batch Traceability & Verification 20 NXP-prefix batch identifiers confirmed across vials and COAs. COA portal at nexaph.coa.swiftcs.ai is searchable by lot number. Janoshik task IDs enable cross-verification through Janoshik's own public database. Specific batch examples publicly confirmed (e.g., CJC0503312025-01). Deduction for fragmented domain infrastructure - the vendor operates across nexaph.com, nexaphresearch.com, nexaphpeptide.com, and nexaph.store with no public explanation of which entity owns or fulfills the product. 15/20
COA Accessibility 15 Public lab results page at nexaph.com/lab-result/ accessible via a checkbox age-gate (not a real account requirement). COA portal at nexaph.coa.swiftcs.ai dedicated to lot-level lookup. Janoshik task IDs on COAs provide an independent verification path through Janoshik's own archive. Gallery/portal format is functional. Minor deduction for the distinction between the gallery page and a fully browseable lot-indexed archive. 11/15
COA Completeness 15 HPLC and mass spectrometry via Janoshik confirmed. Janoshik's standard service covers purity and identity. No publicly documented sterility, endotoxin, or heavy metal panels in the standard batch offering. 9/15
Testing Recency 10 Finnrick tracks ongoing testing activity through 2026 across multiple products. Active testing cadence confirmed from public sources. No evidence of stale placeholder COAs. 8/10
Policy Transparency 5 Refund policy is publicly accessible but unusually restrictive: a quality-based claim requires the researcher to provide independent analytical data (HPLC or MS from a qualified third-party lab) demonstrating a purity discrepancy before Nexaph will review the claim. This shifts the evidentiary burden fully to the buyer. No standard return window for non-defective products. Contact email published (cain@nexaph.com). No company name, no registered entity, no founders named anywhere on the site. 2/5
Operational Track Record 5 Est. 2024. Approximately 2 years of operation. Fragmented operator identity: Finnrick's published analysis maps the vendor through a set of related domains and traces a corporate records trail described as "fragmented rather than a clean public counterparty." No registered entity, state of incorporation, or physical address publicly disclosed. 1/5
Total 63/100
Community Signal
Independent Test Results
Finnrick tracks 265 tests across 11 Nexaph products, with a median passing purity of 99.7%. One documented independent test returned 70% purity on a product claimed at 99% - a 29-point gap. Community members have raised concerns about possible commingling of tested and untested batches under a single published COA. These are Community Signal data points, not VTS dimension inputs, but are relevant context for any researcher evaluating this vendor.
Community Experience
Peptide Critic community rating of 4.8/5 from 91 reviews reflects generally positive buyer experience on shipping speed and product consistency. Trustpilot profile is polarized at 3.8/5: a minority report serious issues while others report smooth transactions. Community discussion in forums notes the kit-only format (10-vial packs) as both a value driver and a friction point for researchers who need smaller quantities.
Scoring Notes
The 70% purity result is the most material public data point
One publicly documented independent test returned 70% purity on a Nexaph product claimed at 99%. VTS does not directly score actual purity results - those belong in the Community Signal field, not the seven-dimension score. But the result is relevant to the Third-Party Testing Practice dimension because it raises a specific question: does the vendor publish all Janoshik test results, or selectively publish passing ones? Janoshik's publication model allows vendors to control which results go public, and Nexaph has not publicly addressed the 70% outlier.
Refund policy as a signal about accountability
Requiring a researcher to commission independent laboratory testing before a quality claim is even reviewed places a significant financial and logistical burden on the buyer. Most vendors in this catalog offer at minimum a straightforward product replacement process. The high evidentiary bar in Nexaph's refund policy is noted because it limits buyer recourse in ways that the score on Policy Transparency reflects.